Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Latanoprost Punctal Plug Delivery System · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Latanoprost Punctal Plug Delivery System followed by Xalatan | EXPERIMENTAL | Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study. |
| Name | Type | Description |
|---|---|---|
| Latanoprost Punctal Plug Delivery System | DRUG | To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study. |
| Xalatan | DRUG | Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study. |
Inclusion Criteria: * Over 18 years * Diagnosed with bilateral Open-Angle Glaucoma or Ocular Hypertension * Currently on prostaglandin therapy Exclusion Criteria: * Uncontrolled medical conditions * Subjects who wear contact lenses * Subjects requiring chronic topical artificial tears, lubricants...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
Latanoprost Punctal Plug Delivery System is an investigational small molecule being studied for ocular hypertension, a condition of elevated pressure inside the eye. It is also being evaluated in patients with open-angle glaucoma. The drug is delivered via a punctal plug, a device inserted into the tear duct to release medication over time.
Latanoprost Punctal Plug Delivery System is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker YCBD. The company is advancing this ophthalmology asset through clinical development, with the drug currently in Phase 2 trials.
Latanoprost Punctal Plug Delivery System is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and effectiveness. One Phase 2 trial has been completed, with no active trials currently ongoing.
Latanoprost Punctal Plug Delivery System has one completed clinical trial, identified as NCT01037036. This Phase 2 study, titled 'A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG,' enrolled 15 participants in the United States with ocular hypertension or open-angle glaucoma. The trial was uncontrolled and not randomized or blinded.
Latanoprost Punctal Plug Delivery System is a small molecule that delivers latanoprost, a prostaglandin analog, through a punctal plug inserted into the tear duct. This mechanism allows for sustained release of the medication to lower intraocular pressure, addressing the underlying pressure elevation in ocular hypertension and open-angle glaucoma.